Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

I’ve been wearing barefoot shoes exclusively for over a decade, on everything from thru-hikes to winter overnights to hours-long urban hikes. Over the years, my feet have become accustomed to the ...

Novo Nordisk's obesity therapy Wegovy put in another strong sales performance in the final quarter of last year, helping to drive group revenue growth of 30% – but don't expect that breakneck ...

Healthcare & Pharmaceuticalscategory· June 10, 2025 Novo Nordisk starts new CagriSema weightloss drug trial Novo Nordisk has launched a new late-stage trial for its experimental next-generation ...

But choosing the right running or walking shoe can make a difference. Healthcare professionals often recommend certain shoes to help self-manage OA knee pain. The type of shoes you wear is ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...

Get the detailed quarterly/annual income statement for Novo Nordisk A/S (NVO). Find out the revenue, expenses and profit or loss over the last fiscal year.

Nasdaq provides Price/Earnings Ratio (or PE Ratio) and PEG ratio for stock evaluation. Financial analysts and individual investors use PE Ratio and PEG ratios to determine the financial ...